ACAD vs AMGN: fair value comparison
ACADIA Pharmaceuticals Inc. and Amgen Inc. · Updated 2026-08-31
Both currently screen as overvalued on TickrTrends' Forward Fair Value model. Within Healthcare, AMGN currently sits closer to the top of our discount ranking. ACAD carries the stronger quality grade.
| ACAD | AMGN | |
|---|---|---|
| Verdict | Overvalued | Overvalued |
| Last price | $25.61 | $432.42 |
| 12-month range | $21.24–$26.29 | $286.92–$385.70 |
| Sector rank | #111 of 113 Healthcare | #104 of 113 Healthcare |
| Quality grade | A | B |
| Momentum grade | — | C |
| Leverage | Low | High |
| Margin trend | Stable | Stable |
| Revenue growth | High | Strong |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | Mixed | Uptrend |
| DCF cross-check | — | Undervalued |
| 52-week position | The top quarter | The top quarter |
Full single-stock breakdowns: ACAD fair value analysis · AMGN fair value analysis